Dianthus Therapeutics DNTH Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $627.67M+6,105% | $51.09M+124% | $55.98M+66.3% | $13.24M-95.8% | $10.12M-96.9% | ||
| $483.59M+91.1% | $353.21M+39.9% | $346.63M+40.1% | $244.15M+425% | $253.11M+435% | ||
| $1.23M+23.0% | $52K— | $5M+260% | $39K-95.4% | $1M— | ||
| $7.42M+9.6% | $5.09M+4.8% | $6.21M+68.7% | $6.18M+86.9% | $6.77M+125% | ||
| $1.12B+313% | $409.44M+45.8% | $413.83M+43.9% | $263.61M-27.9% | $271M-28.9% | ||
| $274K+43.5% | $296K+52.6% | $185K-2.1% | $207K+9.5% | $191K-2.1% | ||
| $1.29M-10.6% | $1.34M-13.9% | $1.31M+271% | $1.38M+212% | $1.45M+173% | ||
| $113.87M— | $110.14M— | $152.87M— | $51.71M— | —— | ||
| $1.25B+258% | $530.92M+42.0% | $577.45M+63.0% | $326.08M-11.6% | $348.58M-8.9% | ||
| $31.13M+290% | $19.45M+48.8% | $15.98M+107% | $14M+139% | $7.98M+36.5% | ||
| $6.32M+242% | $5.77M+202% | $6.07M+848% | $1.79M+162% | $1.85M— | ||
| $399K+76.5% | $367K+14.7% | $217K-30.2% | $211K-44.0% | $226K-43.5% | ||
| $38.28M+126% | $30.73M+66.6% | $23.86M+51.8% | $20.09M+100% | $16.95M+89.2% | ||
| $965K-17.5% | $1.02M-13.0% | $1.07M— | $1.12M+3,630% | $1.17M+1,106% | ||
| —— | —— | $1.29M+313% | $1.33M+227% | $1.4M— | ||
| $45.57M+128% | $37.52M+74.3% | $30.99M+89.5% | $23M+114% | $19.97M+104% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $54K+68.8% | $43K+38.7% | $43K+48.3% | $32K+10.3% | $32K+10.3% | ||
| $1.58B+197% | $829.6M+57.5% | $818.55M+69.4% | $538.48M+12.4% | $532.21M+11.8% | ||
| -$377.56M-85.2% | -$336.73M-93.1% | -$272.3M-86.6% | -$235.53M-95.0% | -$203.9M-97.6% | ||
| -$575K-313% | $489K+361% | $163K-76.1% | $98K+365% | $270K+1,100% | ||
| $1.2B+266% | $493.4M+40.0% | $546.45M+61.7% | $303.08M-15.4% | $328.61M-11.8% | ||
| $1.25B+258% | $530.92M+42.0% | $577.45M+63.0% | $326.08M-11.6% | $348.58M-8.9% | ||
| $1.29M-10.6% | $1.34M-13.9% | $1.31M+271% | $1.38M+212% | $1.45M+173% | ||
| $113.87M— | $110.14M— | $152.87M— | $51.71M— | —— | ||
| $1.29M-10.6% | $1.34M-13.9% | $1.31M+271% | $1.38M+212% | $1.45M+173% | ||
| $11.54M+51.1% | $9.72M+0.9% | $9.26M+95.4% | $9.18M+248% | $7.64M— | ||
| $483.59M+91.1% | $353.21M+39.9% | $346.63M+40.1% | $244.15M+425% | $253.11M— | ||
| $1.29M-10.6% | $1.34M-13.9% | $1.31M+271% | $1.38M+212% | $1.45M+173% | ||
| $31.13M+290% | $19.45M+48.8% | $15.98M+107% | $14M+139% | $7.98M— | ||
| $31.13M+290% | $19.45M+48.8% | $15.98M+107% | $14M+139% | $7.98M— | ||
| $1.49M+210% | $1.19M+148% | $954K+854% | $479K+379% | $479K— | ||
| $6.32M+242% | $5.77M+202% | $6.07M+848% | $1.79M+162% | $1.85M— | ||
| $1.36M-2.3% | $1.39M-7.0% | $1.29M+313% | $1.33M+227% | $1.4M— | ||
| $1.58B+197% | $829.6M+57.5% | $818.55M+69.4% | $538.48M+12.4% | $532.21M+11.8% | ||
| $54K+68.8% | $43K+38.7% | $43K+48.3% | $32K+10.3% | $32K+10.3% | ||
| $0— | $0— | $0— | $0— | $0— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Dianthus Therapeutics cover its short-term obligations?
- Its current ratio is 29.25 — current assets exceed current liabilities.
- Where does Dianthus Therapeutics's balance sheet data come from?
- Every line is extracted from Dianthus Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.